ESR1 and ovarian carcinoma: We also confirmed that ERX-41 has activity against both ER-α+ BC PDX (WHIM-20) (Fig. 6j) and an ovarian cancer cell line xenograft (ES2) (Extended Data Fig. 8f–j), and PDX (OCa-PDX-38) (Fig. 6k).